YU1396A - 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima - Google Patents

2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima

Info

Publication number
YU1396A
YU1396A YU1396A YU1396A YU1396A YU 1396 A YU1396 A YU 1396A YU 1396 A YU1396 A YU 1396A YU 1396 A YU1396 A YU 1396A YU 1396 A YU1396 A YU 1396A
Authority
YU
Yugoslavia
Prior art keywords
ones
medicaments
preparation
application
disubstituted purine
Prior art date
Application number
YU1396A
Other languages
English (en)
Inventor
Ulrich Niewohner
Erwin Bishoff
Helmuth Schutz
Elisabeth Perzobron
Matthias Schramm
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of YU1396A publication Critical patent/YU1396A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

2,9-disupstituisani purin-6-oni, formule I, u kojoj A, R1, R2, R3, R4 imaju značenja data u 1. patentnom zahtevu, pripremaju se kada se u prvom stupnju aciluju odgovarajuće supstituisani aminoimidazoli, pa se zatim ciklizuju u purin. Novi 2,9-disupstituisani purin-6-oni mogu da se upotrebe kao delotvorne supstance u lekovima, naročito za lečenje zapaljivih procesa, tromboembolijskih, srčanih i oboljenja krvotoka, i oboljenja urogenitalnog sistema.
YU1396A 1995-01-19 1996-01-12 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima YU1396A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (1)

Publication Number Publication Date
YU1396A true YU1396A (sh) 1999-03-04

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1396A YU1396A (sh) 1995-01-19 1996-01-12 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima

Country Status (31)

Country Link
US (1) US5861404A (sh)
EP (1) EP0722944A1 (sh)
JP (1) JPH08231545A (sh)
KR (1) KR960029334A (sh)
CN (1) CN1135485A (sh)
AR (1) AR002953A1 (sh)
AU (1) AU4097996A (sh)
BG (1) BG61728B1 (sh)
BR (1) BR9600147A (sh)
CA (1) CA2167353A1 (sh)
CO (1) CO4700523A1 (sh)
CZ (1) CZ16696A3 (sh)
DE (1) DE19501482A1 (sh)
EE (1) EE9600018A (sh)
FI (1) FI960225A (sh)
HR (1) HRP960007A2 (sh)
HU (1) HUP9600106A3 (sh)
IL (1) IL116769A (sh)
MA (1) MA23778A1 (sh)
NO (1) NO960223L (sh)
NZ (1) NZ280830A (sh)
PE (1) PE64996A1 (sh)
PL (1) PL312354A1 (sh)
SG (1) SG50401A1 (sh)
SK (1) SK8096A3 (sh)
SV (1) SV1996000006A (sh)
TN (2) TNSN96006A1 (sh)
TR (1) TR199600028A2 (sh)
TW (1) TW314519B (sh)
YU (1) YU1396A (sh)
ZA (1) ZA96398B (sh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1999003858A1 (fr) * 1997-07-15 1999-01-28 Japan Energy Corporation Derives purine et leur application medicinale
EP1043324B1 (en) 1997-11-12 2004-06-16 Mitsubishi Chemical Corporation Purine derivatives and medicine containing the same as the active ingredient
EP1300147A1 (en) * 1998-01-05 2003-04-09 Eisai Co. Ltd Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
KR100747106B1 (ko) * 1999-05-11 2007-08-08 미쯔비시 가가꾸 가부시끼가이샤 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
ATE552013T1 (de) * 2000-09-06 2012-04-15 Mitsubishi Tanabe Pharma Corp Zubereitungen zur oralen anwendung
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2020205867A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
SK8096A3 (en) 1996-08-07
TW314519B (sh) 1997-09-01
CN1135485A (zh) 1996-11-13
MA23778A1 (fr) 1996-10-01
HU9600106D0 (en) 1996-03-28
EP0722944A1 (de) 1996-07-24
CZ16696A3 (en) 1996-08-14
AU4097996A (en) 1996-07-25
PL312354A1 (en) 1996-07-22
US5861404A (en) 1999-01-19
TR199600028A2 (tr) 1996-08-21
SV1996000006A (es) 1996-10-29
CO4700523A1 (es) 1998-12-29
IL116769A (en) 1998-12-06
KR960029334A (ko) 1996-08-17
SG50401A1 (en) 1998-07-20
DE19501482A1 (de) 1996-07-25
TNSN96006A1 (fr) 2005-03-15
CA2167353A1 (en) 1996-07-20
AR002953A1 (es) 1998-05-27
NO960223D0 (no) 1996-01-18
BG61728B1 (bg) 1998-04-30
HUP9600106A3 (en) 1998-04-28
PE64996A1 (es) 1997-03-09
BR9600147A (pt) 1998-01-06
ZA96398B (en) 1996-08-28
NZ280830A (en) 1998-04-27
JPH08231545A (ja) 1996-09-10
HUP9600106A2 (en) 1997-05-28
FI960225A (fi) 1996-07-20
NO960223L (no) 1996-07-22
HRP960007A2 (en) 1998-02-28
BG100292A (bg) 1996-07-31
IL116769A0 (en) 1996-05-14
FI960225A0 (fi) 1996-01-17
TNSN96007A1 (fr) 2005-03-15
EE9600018A (et) 1996-08-15

Similar Documents

Publication Publication Date Title
YU1396A (sh) 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima
MY124122A (en) Heterocyclic derivatives
FI942074A (fi) nor-sappijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
FI900307A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivista 3-/3-okso-(2,3)-dihydropyridatsin-6-yyli/-2-fenyyli-pyratsolo/1,5-a/pyridiinijohdannaisia
ATE208772T1 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
NO995006L (no) Nye forbindelser
FI951454A (fi) 1-(2-oksoasetyyli)piperidiini-2-karboksyylihappojohdannaiset monille lääkkeille resistenttien syöpäsolujen herkistäjinä
FR2686084B1 (fr) Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
MA26435A1 (fr) Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant.
EP0199822A4 (en) PYRAZOLECARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND BACTERICIDES CONTAINING THEM AS EFFECTIVE INGREDIENTS.
AR011077A1 (es) Un antibiotico cristalino designado forma 0 de solvato de 6-o- metileritromicina a, una composicion que lo comprende, un metodo para tratarinfecciones bacterianas en un mamifero, un procedimiento para preparar dicho solvato; un complejo que comprende dicho solvato, una suspension para administracion
MD1861F2 (en) Derivatives of the 6-arylpyrido[2,3-d]pyrimidines and naphthyridines, pharmaceutical composition on base thereof, methods of treatment and inhibition of the tyrosine kinaze receptor celle proliferation and migration
EP1327452A3 (de) Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und SS-Mimetika
YU1496A (sh) 2,8-disupstituisani hinazolinoni, postupak za njihovo dobijanje i njihova primena
FR2612187B1 (fr) Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
IE863104L (en) Quinolone derivatives
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
LU83820A1 (fr) Derives de la 2-oxoazetidine,leur preparation et leur utilisation
ATE259369T1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
IL88971A (en) Disubstituted pyridines, process and intermediates, their preparation and pharmaceutical compositions containing them
ES8301244A1 (es) Procedimiento para la obtencion de derivados de sisomicina.
DE3852332D1 (de) 4-Thiochinazolin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellungen.
IE801677L (en) An antimycotic vaginal tablet
MD1744F2 (ro) Săruri ale acidului clavulanic şi procedeu de obţinere a lor